Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report) – HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for Avalo Therapeutics in a research note issued on Friday, August 7th. HC Wainwright also issued estimates for Avalo Therapeutics’ Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($2.76) EPS, Q1 2027 earnings at ($0.59) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.62) EPS and FY2027 earnings at ($2.41) EPS. Get Avalo Therapeutics alerts:Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Further ReadingReceive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.